Naltrexone blocks opioid receptors involved in reward and reinforcement. It is used for adults with opioid dependence after detoxification and for alcohol dependence as part of a structured recovery…
Naltrexone blocks opioid receptors involved in reward and reinforcement. It is used for adults with opioid dependence after detoxification and for alcohol dependence as part of a structured recovery plan.
The active substance used clinically is naltrexone hydrochloride, also called Naltrexone HCL. It binds strongly to opioid receptors, especially mu-opioid receptors, without producing the opioid effects associated with medicines such as morphine or codeine.
Naltrexone hydrochloride capsules may be described in clinical records as Naltrexone HCL capsules or prescription Naltrexone capsules. The strength is selected individually. A standard adult regimen is commonly used in licensed clinical practice, while lower-dose preparations may be used only for specific off-label purposes.
| Formulation | Clinical role | Key limitation |
|---|---|---|
| Oral naltrexone capsules | Relapse prevention after opioid detoxification or support for alcohol dependence | Requires reliable daily adherence and an opioid-free starting period |
| Lower-dose naltrexone preparations | Off-label or investigational use in selected conditions | Evidence and dosing protocols vary |
| Extended-release injectable naltrexone | Monthly maintenance in suitable patients | Administered by a healthcare professional; injection reactions can occur |
Naltrexone is used in two main clinical settings:
For opioid use disorder, Naltrexone is started only after the patient has completed withdrawal and no longer has physiological opioid dependence. It is not a substitute for opioid detoxification.
For alcohol dependence, the medicine may help reduce the pleasurable reinforcement associated with alcohol. It does not prevent alcohol withdrawal seizures, delirium tremens, or intoxication. People who drink heavily may need a separate withdrawal-management plan before Naltrexone is considered.
The National Institute for Health and Care Excellence recommends that medication for alcohol dependence should sit within a planned programme involving psychological support, relapse-prevention work, and monitoring [3].
Naltrexone is not suitable for everyone. It is not for you if any of the following apply:
An opioid-free interval is required before treatment begins. The exact interval depends on the opioid used, its half-life, the formulation, and the patient’s clinical condition. Many protocols use at least 7 to 10 days after short-acting opioids, while a longer period may be needed after methadone, buprenorphine, or prolonged-release products.
A naloxone challenge or other clinical assessment may be used when opioid exposure is uncertain. A negative result does not remove the need for careful history-taking and examination.
Liver disease requires special attention. Naltrexone may be unsuitable in acute hepatitis or hepatic failure, while milder hepatic impairment requires individual assessment and appropriate liver-function monitoring. Renal impairment can also influence clinical decisions.
The European Medicines Agency highlights the need to assess opioid status and liver-related precautions before treatment with naltrexone-containing medicines [2].
Do not start Naltrexone if you are still taking opioid painkillers, opioid substitution treatment, or illicit opioids. It is also not suitable if you are in opioid withdrawal, have not completed detoxification, have acute liver disease, or may urgently need opioid pain relief without an alternative plan.
Common adverse effects include:
These effects may be more noticeable during the first days of treatment. Nausea sometimes settles when the capsule is taken with food. Persistent vomiting, marked abdominal pain, dark urine, yellowing of the skin, or unusual tiredness requires prompt medical assessment because these symptoms can indicate liver injury.
Naltrexone can cause serious problems when a person attempts to overcome receptor blockade by taking larger opioid amounts. This may lead to respiratory depression, overdose, coma, or death, especially after tolerance has fallen during detoxification.
With injectable forms, injection-site swelling, pain, induration, infection, or tissue damage can occur. Oral capsules do not cause injection-site reactions.
One practical point is easy to miss: opioid tolerance declines during abstinence. If Naltrexone is later stopped and a person returns to a previous opioid amount, the overdose risk may be much higher than before treatment.
Naltrexone is an opioid antagonist. When these receptors are blocked, opioid medicines and illicit opioids cannot produce their usual euphoria, sedation, or pain-relieving effect. Naltrexone also appears to reduce the reinforcing response associated with alcohol, which can support reduced drinking in people receiving alcohol-dependence treatment. The medicine does not create an opioid “high” and does not provide relief from acute opioid withdrawal.
Naltrexone competes with opioid agonists for receptor binding. Its main clinical effect comes from receptor blockade rather than stimulation. This distinction explains why it can help prevent relapse after opioid detoxification, while also causing sudden and severe withdrawal if opioids remain in the body.
The blockade can also reduce the expected reward from taking an opioid. It does not remove cravings in every patient, and adherence remains a major factor in treatment response. The United States Food and Drug Administration describes oral naltrexone as an opioid antagonist used within treatment programmes for alcohol dependence and opioid dependence [1].
Several mistakes can reduce benefit or create avoidable danger:
A medical alert card or emergency information record can be useful because opioid analgesia may need specialist planning during acute pain.
The World Health Organization describes opioid withdrawal management and relapse-prevention treatment as separate stages requiring clinical planning and monitoring [4].
Naltrexone, Disulfiram, and Naloxone have different clinical roles. Choosing among them depends on the treatment target, opioid status, liver function, adherence, and the need for emergency treatment.
| Medicine | Main action and use | Practical distinction |
|---|---|---|
| Naltrexone | Blocks opioid receptors; supports relapse prevention in opioid or alcohol dependence | Requires opioid abstinence before starting |
| Disulfiram | Produces an unpleasant reaction when alcohol is consumed | Works through alcohol sensitivity rather than opioid-receptor blockade |
| Naloxone | Rapidly reverses opioid-induced respiratory depression | Emergency medicine, not routine relapse-prevention treatment |
Disulfiram is generally used when the treatment plan includes a clear commitment to avoiding alcohol and supervised adherence is possible. Naltrexone may be preferred when reducing alcohol reward or preventing opioid effects is the clinical goal.
Naloxone is carried or administered for suspected opioid overdose. It acts quickly in an emergency but does not provide the planned maintenance blockade of Naltrexone.
In clinical practice, prescribers often focus first on opioid-free status rather than on the convenience of a daily capsule. A patient who still has opioids in the system may experience abrupt withdrawal after the first dose.
Doctors also assess whether daily adherence is realistic. Missed doses reduce protection against relapse, while stopping Naltrexone can leave a person with reduced opioid tolerance and increased overdose vulnerability.
For alcohol dependence, clinicians usually combine Naltrexone with relapse-prevention counselling, drinking-goal monitoring, and assessment of liver health. Medication can reduce reinforcement, but it does not replace treatment of stress, trauma, depression, or social triggers that drive drinking.
One oral dose produces opioid-receptor blockade for a clinically useful period, but the degree and duration vary with metabolism, liver function, adherence, and the opioid involved. The effect should not be judged by taking extra capsules or opioids. FDA prescribing information from 2022 describes oral Naltrexone as a planned antagonist treatment rather than an emergency medicine. Clinical monitoring remains important during the first treatment days and after missed doses. The FDA label from 2022 does not support using extra doses to extend blockade.
Naltrexone may be taken with or without food when prescribed orally. Food can be useful if the capsule causes nausea or stomach discomfort. A light meal is often easier to tolerate than a heavy, fatty meal. HPRA product information for medicines in this class should guide the specific administration plan in 2026, with the prescriber’s individual instructions taking priority.
Naltrexone can be prescribed alongside some non-opioid medicines, but the full medicine list must be reviewed. The major interaction is with opioid medicines, including analgesics, methadone, and buprenorphine. Alcohol-related supplements and herbal products may also affect the liver or cause sedation. The EMA product information from 2010 assesses interactions according to the complete treatment regimen, not only the named active ingredient.
Acute hepatitis or hepatic failure rules out treatment, and current opioid dependence or acute opioid withdrawal also prevents safe initiation. Naltrexone must not be started while opioid analgesics or opioid-substitution medicines are still being used without a supervised transition plan. The FDA prescribing information from 2022 identifies opioid-free status as a central safety requirement. Liver symptoms such as jaundice or dark urine require prompt clinical assessment.
Do not increase the dose or add opioids independently. The prescriber may review adherence, the diagnosis, the opioid-free interval, alcohol intake, liver function, cravings, and psychological support. NICE guidance from 2011 recommends combining medication for alcohol dependence with structured psychosocial treatment rather than judging the medicine in isolation. A similar review is needed for opioid use disorder if cravings or relapse risk remain high.
Older adults may use Naltrexone when the benefits outweigh the risks, but age-related changes in liver and kidney function can affect prescribing decisions. Other medicines are also more common in later life, increasing the chance of interactions or duplicate opioid exposure. The dose is decided individually, taking age, other medicines, and health conditions into account. WHO treatment principles from 2009 support careful assessment, monitoring, and coordination of medicines in older patients.
Nausea is a recognised adverse effect of oral Naltrexone and may be most noticeable soon after treatment begins. Taking the capsule with a light meal can improve tolerability for some people, although persistent vomiting requires assessment. The FDA product information from 2022 lists gastrointestinal symptoms among reported reactions. Severe abdominal pain, jaundice, or dark urine needs prompt medical review because liver injury must be considered.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 5 reviews
I used oral Naltrexone after completing an alcohol programme. The first week brought nausea and poor sleep, but taking the capsule after breakfast made it easier. After about a month, alcohol felt less rewarding, although counselling was still the main part of my routine.
About a month 3 Nov 2026I had been opioid-free before starting treatment and did not experience withdrawal from the first dose. My main complaint was headache during the first several days. The medicine helped reduce the fear of relapse, but I still needed reminders to take it consistently.
The first several days 9 Nov 2026Naltrexone reduced the appeal of drinking for me. I took it for several weeks and noticed fewer urges, though the effect was not immediate. Missing doses made the cravings feel more noticeable again.
Several weeks 12 Oct 2026The capsules caused stomach discomfort when I took them without food. A light breakfast helped. I also learned that ordinary painkillers containing codeine were not suitable while I was taking Naltrexone, which was something I had not expected.
18 Oct 2026Treatment was useful after detoxification, but I found the daily routine difficult during shift work. I had no major side effects, yet the medicine did not solve every trigger for drinking. Structured support remained necessary.
25 Oct 2026
